Zealand Pharma A/S
CSE:ZEAL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
310.8
805
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 526.2 DKK,
Zealand Pharma A/S
is
hidden
.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Zealand Pharma A/S
ZEAL looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether ZEAL usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Zealand Pharma A/S.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Zealand Pharma A/S
Balance Sheet Decomposition
Zealand Pharma A/S
| Current Assets | 16.6B |
| Cash & Short-Term Investments | 16.2B |
| Receivables | 224.7m |
| Other Current Assets | 226.9m |
| Non-Current Assets | 176.2m |
| PP&E | 141.4m |
| Intangibles | 12.7m |
| Other Non-Current Assets | 22.1m |
| Current Liabilities | 1.2B |
| Accounts Payable | 243.9m |
| Other Current Liabilities | 934.7m |
| Non-Current Liabilities | 456.1m |
| Long-Term Debt | 383.9m |
| Other Non-Current Liabilities | 72.2m |
Free Cash Flow Analysis
Zealand Pharma A/S
| DKK | |
| Free Cash Flow | DKK |
Earnings Waterfall
Zealand Pharma A/S
|
Revenue
|
9.2B
DKK
|
|
Cost of Revenue
|
-1.2m
DKK
|
|
Gross Profit
|
9.2B
DKK
|
|
Operating Expenses
|
-1.9B
DKK
|
|
Operating Income
|
7.3B
DKK
|
|
Other Expenses
|
-724.1m
DKK
|
|
Net Income
|
6.5B
DKK
|
ZEAL Profitability Score
Profitability Due Diligence
Zealand Pharma A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Zealand Pharma A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.
ZEAL Solvency Score
Solvency Due Diligence
Zealand Pharma A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Zealand Pharma A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZEAL Price Targets Summary
Zealand Pharma A/S
According to Wall Street analysts, the average 1-year price target for
ZEAL
is 766.08 DKK
with a low forecast of 404 DKK and a high forecast of 1 176 DKK.
Dividends
Current shareholder yield for
ZEAL is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ZEAL
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 526.2 DKK,
Zealand Pharma A/S
is
hidden
.